The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Speakers' Bureau - Bristol-Myers Squibb; Novartis
A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).
 
Michael J. Mauro
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Novartis; Pfizer
 
Andreas Hochhaus
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Carla Boquimpani
No Relationships to Disclose
 
Yosuke Minami
Honoraria - Ono Pharmaceutical; Otsuka
Consulting or Advisory Role - Amgen; Novartis; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Novartis; Pfizer
Research Funding - Celgene (Inst); Chugai Pharma (Inst); Eisai (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Takeda (Inst)
 
Alex Allepuz
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Fotis Polydoros
Employment - Novartis
 
Véronique Bédoucha
No Relationships to Disclose
 
Paola Aimone
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Delphine Réa
Honoraria - Bristol-Myers Squibb; Incyte; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis